[Systematic review of anti-tuberculosis drug induced adverse reactions in China].
OBJECTIVE
To study the incidences of adverse reactions induced by anti-tuberculosis drugs in China.


METHODS
Articles about adverse drug reactions (ADR) induced by anti-tuberculosis drugs published in 1996 - 2005 in China were searched. The incidences, possible risk factors, and prognoses of these ADR were analyzed.


RESULTS
According to our searching strategy and including criteria, 117 studies were included. The overall incidence of anti-tuberculosis drug induced ADR of these studies was 12.62%, and the overall incidence of hepatic injury was 11.9%, which was the highest among all kinds of ADR induced by anti-tuberculosis therapy. For different types of study, different diagnostic standards of hepatic injury, and different study institutions, the reported incidences of hepatic injury varied. Retrospective cohort studies showed that HBV(+) tuberculosis patients had a significantly higher risk of hepatic injury than HBV(-) patients. The prognosis of hepatic injury was good; 85.84% patients were cured of hepatic injury according to the articles which reported outcomes. The whole study was finished by 2006.


CONCLUSIONS
The incidence of adverse reactions induced by anti-tuberculosis drugs is high in China. Prevention and treatment of ADR are very important for improving the adherence of patients.
Xia
Yin-yin
YY
Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100083, China.
Zhan
Si-yan
SY
D000995:Antitubercular Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury; D002681:China / Q000453:epidemiology; D064420:Drug-Related Side Effects and Adverse Reactions / Q000139:chemically induced / Q000175:diagnosis* / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007538:Isoniazid / Q000009:adverse effects; D008107:Liver Diseases / Q000175:diagnosis / Q000453:epidemiology; D012293:Rifampin / Q000009:adverse effects; D014376:Tuberculosis / Q000188:drug therapy*
D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin